Danish pharma major Novo Nordisk (NOV: N) announced last month that the company had experienced a growth in the sales of Ozempic (semaglutide), which is indicated for type 2 diabetes (T2D).
According to data and analytics provider GlobalData, this increase may be attributed to supply shortages of Wegovy (semaglutide), indicated for obesity, due to its high demand and manufacturer production problems.
"Wegovy shows potential for the greatest amount of weight reduction among approved therapies for obesity"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze